These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37087871)

  • 1. Efficacy of the modified vaccinia Ankara virus vaccine and the replication-competent vaccine ACAM2000 in monkeypox prevention.
    Kandeel M; Morsy MA; Abd El-Lateef HM; Marzok M; El-Beltagi HS; Al Khodair KM; Albokhadaim I; Venugopala KN
    Int Immunopharmacol; 2023 Jun; 119():110206. PubMed ID: 37087871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques.
    Jacob-Dolan C; Ty D; Hope D; McMahan K; Liu J; Powers OC; Cotter CA; Sciacca M; Wu C; Borducchi E; Bouffard E; Richter H; Velasco J; Teow E; Boursiquot M; Cook A; Feliciano K; Yalley-Ogunro J; Seaman MS; Pessiant L; Lewis MG; Andersen H; Moss B; Barouch DH
    Sci Transl Med; 2024 Mar; 16(740):eadl4317. PubMed ID: 38536937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo.
    Priyamvada L; Carson WC; Ortega E; Navarra T; Tran S; Smith TG; Pukuta E; Muyamuna E; Kabamba J; Nguete BU; Likafi T; Kokola G; Lushima RS; Tamfum JM; Okitolonda EW; Kaba DK; Monroe BP; McCollum AM; Petersen BW; Satheshkumar PS; Townsend MB
    Vaccine; 2022 Nov; 40(50):7321-7327. PubMed ID: 36344361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
    Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
    N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Rao AK; Petersen BW; Whitehill F; Razeq JH; Isaacs SN; Merchlinsky MJ; Campos-Outcalt D; Morgan RL; Damon I; Sánchez PJ; Bell BP
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(22):734-742. PubMed ID: 35653347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications and Adverse Effects of JYNNEOS and ACAM2000 Monkeypox Vaccines.
    Meo SA; Al-Masri AA; Klonoff DC; Alshahrani AN; Al-Khlaiwi T
    Vaccines (Basel); 2022 Nov; 10(11):. PubMed ID: 36423066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
    Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
    Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox - United States, May 22-October 10, 2022.
    Kriss JL; Boersma PM; Martin E; Reed K; Adjemian J; Smith N; Carter RJ; Tan KR; Srinivasan A; McGarvey S; McGehee J; Henderson D; Aleshire N; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(43):1374-1378. PubMed ID: 36301741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection - New York, 2022.
    Rosenberg ES; Dorabawila V; Hart-Malloy R; Anderson BJ; Miranda W; O'Donnell T; Gonzalez CJ; Abrego M; DelBarba C; Tice CJ; McGarry C; Mitchell EC; Boulais M; Backenson B; Kharfen M; McDonald J; Bauer UE
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):559-563. PubMed ID: 37339074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak - United States, May 22-October 21, 2022.
    Duffy J; Marquez P; Moro P; Weintraub E; Yu Y; Boersma P; Donahue JG; Glanz JM; Goddard K; Hambidge SJ; Lewin B; Lewis N; Rouse D; Shimabukuro T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(49):1555-1559. PubMed ID: 36480476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mpox: Rapid Evidence Review.
    Saguil A; Krebs L; Choe U
    Am Fam Physician; 2023 Jul; 108(1):78-83. PubMed ID: 37440743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022.
    Payne AB; Ray LC; Cole MM; Canning M; Houck K; Shah HJ; Farrar JL; Lewis NM; Fothergill A; White EB; Feldstein LR; Roper LE; Lee F; Kriss JL; Sims E; Spicknall IH; Nakazawa Y; Gundlapalli AV; Shimabukuro T; Cohen AL; Honein MA; Mermin J; Payne DC
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(49):1560-1564. PubMed ID: 36480479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals.
    Zaeck LM; Lamers MM; Verstrepen BE; Bestebroer TM; van Royen ME; Götz H; Shamier MC; van Leeuwen LPM; Schmitz KS; Alblas K; van Efferen S; Bogers S; Scherbeijn S; Rimmelzwaan GF; van Gorp ECM; Koopmans MPG; Haagmans BL; GeurtsvanKessel CH; de Vries RD
    Nat Med; 2023 Jan; 29(1):270-278. PubMed ID: 36257333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study.
    Cohn H; Bloom N; Cai GY; Clark JJ; Tarke A; Bermúdez-González MC; Altman DR; Lugo LA; Lobo FP; Marquez S; ; Chen JQ; Ren W; Qin L; Yates JL; Hunt DT; Lee WT; Crotty S; Krammer F; Grifoni A; Sette A; Simon V; Coelho CH
    Lancet Infect Dis; 2023 Nov; 23(11):1302-1312. PubMed ID: 37475115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status of Vaccine Development for Monkeypox Virus.
    Rastogi A; Kumar M
    Adv Exp Med Biol; 2024; 1451():289-300. PubMed ID: 38801585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study - United States, August 19, 2022-March 31, 2023.
    Dalton AF; Diallo AO; Chard AN; Moulia DL; Deputy NP; Fothergill A; Kracalik I; Wegner CW; Markus TM; Pathela P; Still WL; Hawkins S; Mangla AT; Ravi N; Licherdell E; Britton A; Lynfield R; Sutton M; Hansen AP; Betancourt GS; Rowlands JV; Chai SJ; Fisher R; Danza P; Farley M; Zipprich J; Prahl G; Wendel KA; Niccolai L; Castilho JL; Payne DC; Cohn AC; Feldstein LR; ;
    MMWR Morb Mortal Wkly Rep; 2023 May; 72(20):553-558. PubMed ID: 37200229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Demographic and Clinical Characteristics of Mpox in Persons Who Had Previously Received 1 Dose of JYNNEOS Vaccine and in Unvaccinated Persons - 29 U.S. Jurisdictions, May 22-September 3, 2022.
    Farrar JL; Lewis NM; Houck K; Canning M; Fothergill A; Payne AB; Cohen AL; Vance J; Brassil B; Youngkin E; Glenn B; Mangla A; Kupferman N; Saunders K; Meza C; Nims D; Soliva S; Blouse B; Henderson T; Banerjee E; White B; Birn R; Stadelman AM; Abrego M; McLafferty M; Eberhart MG; Pietrowski M; De León SM; Creegan E; Diedhiou A; Wiedeman C; Murray-Thompson J; McCarty E; Marcinkevage J; Kocharian A; Torrone EA; Ray LC; Payne DC;
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1610-1615. PubMed ID: 36580416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea.
    Lim SY; Jung YM; Kim Y; Kim G; Jeon J; Chin B; Kim MK
    J Korean Med Sci; 2024 Mar; 39(8):e100. PubMed ID: 38442725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced Odds of Mpox-Associated Hospitalization Among Persons Who Received JYNNEOS Vaccine - California, May 2022-May 2023.
    Schildhauer S; Saadeh K; Vance J; Quint J; Salih T; Lo T; Keinde A; Chojolan E; Gotlieb E; Ramos M; Chapman E; Peters P; Watson J; Johnson KA; Tang EC; Jacobson K; Snyder RE
    MMWR Morb Mortal Wkly Rep; 2023 Sep; 72(36):992-996. PubMed ID: 37676838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox - United States, May 22, 2022-January 31, 2023.
    Owens LE; Currie DW; Kramarow EA; Siddique S; Swanson M; Carter RJ; Kriss JL; Boersma PM; Lee FC; Spicknall I; Hurley E; Zlotorzynska M; Gundlapalli AV
    MMWR Morb Mortal Wkly Rep; 2023 Mar; 72(13):342-347. PubMed ID: 36995962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.